Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML

D. DiNardo, Courtney; M. Stein, Eytan; de Botton, Stéphane; J. Roboz, Gail; K. Altman, Jessica; S. Mims, Alice; Swords, Ronan; H. Collins, Robert; N. Mannis, Gabriel; A. Pollyea, Daniel; Donnellan, Will; T. Fathi, Amir; Pigneux, Arnaud; P. Erba, Harry; T. Prince, Gabrielle; S. Stein, Anthony; L. Uy, Geoffrey; M. Foran, James; Traer, Elie; K. Stuart, Robert; Arellano, Martha; L. Slack, James; A. Sekeres, Mikkael; Willekens, Christophe; Choe, Sung; Wang, Hongfang; Zhang, Vickie; Yen, Katharine; M. Kapsalis, Stephanie; Yang, Hua; L. Dai, David; Fan, Bin; A. Goldwasser, Meredith; Liu, Hua; Agresta, Sam; Wu, Bin; C. Attar, Eyal; S. Tallman, Martin; M. Stone, Richard; M. Kantarjian, Hagop

doi:10.1056/nejmoa1716984

Public

Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AML

Published in New England Journal of Medicine • Jun 2, 2018

Authors:

Courtney D. DiNardo

Eytan M. Stein

Stéphane de Botton

Abstract

BACKGROUND: Mutations in the gene encoding isocitrate dehydrogenase 1 ( IDH1) occur in 6 to 10% of patients with acute myeloid leukemia (AML). Ivosidenib (AG-120) is an oral, targeted, small-molecule inhibitor of mutant IDH1. METHODS: We conducted a phase 1 dose-escalation and dose-expansion study o...

Subject

Medicine

Internal medicine

Refractory (planetary science)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!